Drs. Hsia, Beutler, Doyle, Hsu, and Rahman and Mr. Xu own stock and/or stock options in Johnson & Johnson, of which Janssen Research & Development, LLC, is a subsidiary.
Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti–tumor necrosis factor antibody, in Phase III clinical trials
Version of Record online: 30 JAN 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 2, pages 309–313, February 2013
How to Cite
Hsia, E. C., Cush, J. J., Matteson, E. L., Beutler, A., Doyle, M. K., Hsu, B., Xu, S. and Rahman, M. U. (2013), Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti–tumor necrosis factor antibody, in Phase III clinical trials. Arthritis Care Res, 65: 309–313. doi: 10.1002/acr.21788
- Issue online: 30 JAN 2013
- Version of Record online: 30 JAN 2013
- Accepted manuscript online: 10 JUL 2012 11:38AM EST
- Manuscript Accepted: 22 JUN 2012
- Manuscript Received: 7 FEB 2012
- Janssen Research & Development, LLC
- Merck (formerly Schering-Plough)
- 2Cellestis. QuantiFERON-TB Gold clinicians guide and QuantiFERON-TB Gold In-Tube method package insert. URL: www.cellestis.com.
- 3Oxford Immunotec. T-SPOT.TB. URL: http://www.oxfordimmunotec.com/T-SPOT_International.
- 4Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti–tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012; 64: 2068–77., , , , , , et al.
- 7START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006; 54: 1075–86., , , , , , et al, for the